BIOAVAILABILITY AND CHEMOTHERAPEUTIC ACTIVITY OF CLOFAZIMINE AGAINST MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN BEIGE MICE FOLLOWING A SINGLE IMPLANT OF A BIODEGRADABLE POLYMER

被引:22
作者
KAILASAM, S
WISE, DL
GANGADHARAM, PRJ
机构
[1] UNIV ILLINOIS,COLL MED,INFECT DIS SECT,MYCOBACTERIOL RES LABS,CHICAGO,IL 60612
[2] NORTHEASTERN UNIV,DEPT CHEM ENGN,BOSTON,MA 02115
关键词
D O I
10.1093/jac/33.2.273
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We have studied the bioavailability of clofazimine following administration of a single dose of the drug in the biodegradable polymer polylactic-co-glycolic acid (PLGA). We compared the levels of clofazimine achieved in the liver with single implants with those obtained with daily oral treatment. Even though the levels achieved with implants were much lower than those obtained after daily oral treatment, they were higher than the MIC of clofazimine for Mycobacterium leprae, Mycobacterium tuberculosis and Mycobacterium avium complex (MAC). Experimental studies in beige mice after infection with MAC strain 101 showed similar reductions in cfu counts, after both single dose polymer and daily oral treatment. Macroscopically, hyperpigmentation giving an orange-yellow colour to all visceral organs, was seen in animals after daily oral treatment but not in those animals that received polymer implants. © 1994 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:273 / 279
页数:7
相关论文
共 20 条
[1]  
BARRY V C, 1960, Ir J Med Sci, V416, P345
[2]  
BARRY V C, 1969, Scientific Proceedings of the Royal Dublin Society Series A, V3, P153
[3]   CONFIRMATION OF THE BEIGE MOUSE MODEL FOR STUDY OF DISSEMINATED INFECTION WITH MYCOBACTERIUM-AVIUM COMPLEX [J].
BERTRAM, MA ;
INDERLIED, CB ;
YADEGAR, S ;
KOLANOSKI, P ;
YAMADA, JK ;
YOUNG, LS .
JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (01) :194-195
[4]   INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].
FERNANDES, PB ;
HARDY, DJ ;
MCDANIEL, D ;
HANSON, CW ;
SWANSON, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534
[5]   COMPLIANCE OF PATIENTS AND PHYSICIANS - EXPERIENCE AND LESSONS FROM TUBERCULOSIS .2. [J].
FOX, W .
BMJ-BRITISH MEDICAL JOURNAL, 1983, 287 (6385) :101-105
[7]   AN ACUTE INFECTION MODEL FOR MYCOBACTERIUM-INTRACELLULARE DISEASE USING BEIGE MICE - PRELIMINARY-RESULTS [J].
GANGADHARAM, PR ;
EDWARDS, CK ;
MURTHY, PS ;
PRATT, PF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (05) :648-649
[8]   EXPERIMENTAL CHEMOTHERAPY OF TUBERCULOSIS USING SINGLE-DOSE TREATMENT WITH ISONIAZID IN BIODEGRADABLE POLYMERS [J].
GANGADHARAM, PRJ ;
KAILASAM, S ;
SRINIVASAN, S ;
WISE, DL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (02) :265-271
[9]   ACTIVITY OF RIFABUTIN ALONE OR IN COMBINATION WITH CLOFAZIMINE OR ETHAMBUTOL OR BOTH AGAINST ACUTE AND CHRONIC EXPERIMENTAL MYCOBACTERIUM-INTRACELLULARE INFECTIONS [J].
GANGADHARAM, PRJ ;
PERUMAL, VK ;
JAIRAM, BT ;
RAO, PN ;
NGUYEN, AK ;
FARHI, DC ;
ISEMAN, MD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (02) :329-333
[10]   THE BEIGE MOUSE MODEL FOR MYCOBACTERIUM-AVIUM COMPLEX (MAC) DISEASE - OPTIMAL CONDITIONS FOR THE HOST AND PARASITE [J].
GANGADHARAM, PRJ ;
PERUMAL, VK ;
FARHI, DC ;
LABRECQUE, J .
TUBERCLE, 1989, 70 (04) :257-271